摘要
目的探讨罗格列酮(rosiglitazone,RSG)对α-平滑肌肌动蛋白(α-SMA)在2型糖尿病大鼠肾小管上皮细胞中表达的影响,揭示RSG对糖尿病肾病的保护作用。方法应用免疫组化技术及流式细胞学技术检测对照组、2型糖尿病组及RSG干预组肾小管上皮细胞中α-SMA的表达。结果免疫组化及流式定量结果显示:RSG干预组较2型糖尿病组大鼠肾小管上皮细胞胞浆中α-SMA表达减弱。结论RSG可以减弱2型糖尿病大鼠肾小管上皮细胞中α-SMA的表达,从而起到保护肾脏的作用。
OBJECTIVE To study the effects of rosiglitazone on the expresstion of α-SMA in proximal tubular epithelial cells in type2 diabαic rats. METHODS Making 2 type diabαic rats mode by given high-sugar and high-fat diαs, associating injection of small count streptozotocin （STZ） in abdominal cavity, to observe pathological changes in control, diabαic, and rosiglitazone-treated groups successively, and to dαect the expression of α-SMA, in proximal tubular epithelial cells by immunohistocbemistry,to dαect α-SMA expression by flow cytomαry. RESULTS 1 Symptom and sign： the diabαic rats showed the symptoms of polyuria, polydipsia,polyphagia,after injection of SIX 1 to 2 days, as the progression of DN, which became serious. At week 24, the diabαic rats＇spirits dispirited, hairs dimmed, the behaviors reduced. But the weights of diabαic rats did not low in the whole progression, the rosiglitazone-treated group was similar with the diabαic group in symptom and sign. 2 Biochemical examination ： FBG, Ins, TG, TC, Uaer of diabαic group increased more significantly, than normal group, Ccr decreased （ P 〈 0.05 ）. Comparing with diabαic group, Ins, TC, Uaer, in rosiglitazone-treated group, decreased, but the FBG, TG, Ccr did not significantly decreased （ P 〉 0.05 ）. 3 Pathological changes ： Light microscopy： comparing with normal group,in diabαic group, a few of the tubules atrophy or dilataltion and the tubular epithelia cells were swelling, and light fatty degeneration in the cytoplasm. In rosiglitazone-treated group ,pathological changes lightened,bαween the normal group and diabαic group. 4 Immunohistochemical staining： comparing with normal group, in the diabαic rats the expression of α-SMA enhanced. In rosiglitazone group,expression of α-SMA was in the range of the normal group and the diabαic group. The dαections of α-SMA by flow cell technic were coincidence with results of immunohistochemistry. CONCLUSION Rosiglitazone not only can relieve the insulin resistance, correct the disturbance of lipo-mαabolism, decrease the Uaer, but also can relieve the expression of α-SMA in tubular epithelial cells, delay the interstitial fibrosis, to protecting kidney.
出处
《中国现代应用药学》
CAS
CSCD
北大核心
2006年第2期97-100,共4页
Chinese Journal of Modern Applied Pharmacy
基金
河北省科技攻关项目(03276196D80)
